Novacea leads with $25 million in third round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Novacea
|
$25M
|
Apax Partners |
The funding is earmarked to launch a Phase III clinical trial of DN-101 in advanced prostate cancer. |
|
Xytis
|
$24.5M
|
Sanderling Ventures |
The money will go to preclinical and Phase I and II studies of experimental therapies for CNS disorders. |
|
Tioga Pharmaceuticals
|
$24M
|
Forward Ventures |
The company has plans to advance a new therapy into Phase IIa and IIb for asimadoline. |
|
CanBas
|
$20M
|
NIF SMBC Ventures |
CBP501 is currently under investigation in Phase I as a G2 checkpoint blocker. |
|
Athenix
|
$13M
|
Finistere Partners |
Athenix will use proceeds to continue moving products from their portfolio through field trials to registration. |
|
EraGen Biosciences
|
$12M
|
First Analysis Corporation |
EraGen is currently engaged in molecular diagnostics. |
|
Cetek
|
$10M
|
Argonaut Private Equity |
The funding will advance the company's drug discovery platform and bolster its emerging pipeline of compounds to treat cancer, HIV and Hepatitis C. |
|
Hawaii Biotech
|
$7.8M
|
Board Chairman Nick Mitsakos |
The company has been developing an anti-inflammatory compound. |